Amendment No. 3 to the 2002 Agreement between Discovery
Partners International, Inc and Pfizer Inc
Execution of this letter amendment (“Amendment No. 3”) between Pfizer Inc (“Pfizer”) and Discovery Partners International,
Inc. (“DPI”), will serve to amend an agreement between the parties, effective as of January 5, 2002 (the “2002 Agreement”) as
amended on June 20 and August 13, 2002 (such amendments being, respectively, “Amendment No. 1” and “Amendment No. 2”
and, together with the 2002 Agreement, the “Agreement”).
Whereas , the Agreement provides for a program between DPI and Pfizer to design and provide Pfizer with protocols and
procedures useful in the production of pharmacologically relevant compounds, and to prosecute said protocols and procedures
to synthesize libraries of Pfizer exclusive compounds for Pfizer’s chemical files; and
Whereas , the parties now wish to further amend the Agreement, and
Now therefore , the parties agree as follows:
1 Scope of Amendment No.3 . This Amendment No. 3 modifies and amends the Agreement only to the extent
expressly specified herein. Unless expressly specified otherwise herein, all terms and conditions of the Agreement
shall remain unchanged and shall continue in full force and effect.
2 Definitions . Capitalized terms used in this Amendment No. 3 shall have the same meanings as given in the
3 Section 4 . Solely for the purposes of Section 4 of the Agreement the term “Commitment Year 1” shall mean the
period beginning on the Effective Date and ending on *** or such earlier date as *** Compounds have been
delivered to Pfizer; and the term “Commitment Year 2” shall mean the period beginning at the end of Commitment
Year 1 and ending on the second anniversary of the Effective Date.
4 Exhibit A, Schedule 4.1 (“Criteria for Library Production”) is amended under Subheading, “Identity and
Purification Specs” by adding a new sentence after the existing third sentence, reading: “In the alter